Jefferies Financial Group Inc. bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,700 shares of the company’s stock, valued at approximately $1,959,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in MEDP. BlackRock Inc. acquired a new stake in shares of Medpace during the 2nd quarter valued at about $1,323,047,000. AQR Capital Management LLC raised its position in Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after acquiring an additional 324,293 shares in the last quarter. Wasatch Advisors LP lifted its stake in shares of Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after acquiring an additional 24,625 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after purchasing an additional 85,517 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In other news, CEO August J. Troendle sold 4,000 shares of Medpace stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $620.03, for a total transaction of $2,480,120.00. Following the sale, the chief executive officer directly owned 540,544 shares in the company, valued at approximately $335,153,496.32. The trade was a 0.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brian T. Carley sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the sale, the director directly owned 27,825 shares in the company, valued at approximately $16,935,129.75. The trade was a 15.23% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 133,821 shares of company stock valued at $81,748,135. 20.50% of the stock is owned by insiders.
Medpace Stock Down 1.8%
Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter last year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts recently commented on MEDP shares. Mizuho lifted their target price on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. TD Cowen increased their target price on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Royal Bank Of Canada raised their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and lifted their price target for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, Medpace has a consensus rating of “Hold” and an average price target of $584.18.
Check Out Our Latest Analysis on Medpace
Medpace Profile
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
- Five stocks we like better than Medpace
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
